Skip to main content

Clinical Trials

Please use the search below. See our frequently asked questions regarding clinical trials. 

Showing 1 - 10 of 163

Valiant Evo US Clinical Trial

The purpose of the Valiant Evo US Clinical Trial is to demonstrate the safety and effectiveness of the Valiant Evo Thoracic Stent Graft System in subjects with a descending thoracic aortic aneurysm (DTAA) who are candidates for endovascular repair. The clinical evidence collected as part of this trial will be used in conjunction with data collected during the concurrently enrolling Valiant Evo International Clinical Trial to support PMA-S Approval of the Valiant Evo Thoracic Stent Graft System.

Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy- Astra Zeneca

This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy.

A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer

The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.

A Phase I, dose escalation, safety and Pharmacokinetic study of PF-06647020 in adult patients with advanced solid tumors (Pfizer B7661001)

This phase I trial is designed to assess safety and tolerability at increasing dose levels of PF-06647020 administered intravenously on an every 21-day dosing schedule to patients with advanced solid tumors unresponsive to currently available therapies, or for whom no standard therapy is available.

Fairfax Stem Cell Transplant Program: Autologous Transplantation Recipient and Allogeneic Related Donor Data Collection

As a transplant program we are required to collect data to document the quality of our program, maintain accreditation with national and international societies, and to enhance our understanding of stem cell transplant and the response patients have to transplant. Our transplant center sends transplant related information to US Oncology (network that we are affiliated with), the Inova Fairfax Hospital Stem Cell Transplant team, and the Center for International Blood and Bone Marrow Transplant Research (CIBMTR). For those patients having a matched unrelated donor transplant, information will be sent to the National Marrow Donor Program (NMDP). On occasion we supply statistical information to federal and state agencies and insurance companies without specific reference to individual patients.

Showing 1 - 10 of 163